AVELUMAB for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 104 adverse event reports in the FDA FAERS database where AVELUMAB was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for AVELUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 361 | 9.9% | 361 | 35 |
| Disease progression | 355 | 9.8% | 207 | 65 |
| Off label use | 200 | 5.5% | 56 | 55 |
| Diarrhoea | 153 | 4.2% | 17 | 84 |
| Infusion related reaction | 142 | 3.9% | 14 | 51 |
| Pyrexia | 129 | 3.6% | 18 | 90 |
| Fatigue | 124 | 3.4% | 19 | 36 |
| Neoplasm progression | 119 | 3.3% | 69 | 29 |
| Dyspnoea | 100 | 2.8% | 15 | 66 |
| Nausea | 99 | 2.7% | 15 | 50 |
| Chills | 98 | 2.7% | 6 | 37 |
| Interstitial lung disease | 96 | 2.6% | 19 | 46 |
| Hypertension | 89 | 2.5% | 6 | 35 |
| Rash | 83 | 2.3% | 7 | 24 |
| Acute kidney injury | 82 | 2.3% | 14 | 67 |
Other Indications for AVELUMAB
Transitional cell carcinoma (554)
Product used for unknown indication (439)
Neuroendocrine carcinoma of the skin (401)
Renal cell carcinoma (316)
Metastatic renal cell carcinoma (170)
Bladder cancer (167)
Transitional cell carcinoma metastatic (144)
Non-small cell lung cancer (132)
Neoplasm malignant (90)
Ovarian cancer (84)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)
GEMCITABINE\GEMCITABINE (68)